Abstract
A consortium of translational stem cell and stroke experts from multiple academic institutes and biotechnology companies, under the guidance of the government (FDA/NIH), is missing. Here, we build a case for the establishment of this consortium if cell therapy for stroke is to advance from the laboratory to the clinic.
Original language | English (US) |
---|---|
Pages (from-to) | 691-693 |
Number of pages | 3 |
Journal | Cell Transplantation |
Volume | 18 |
Issue number | 7 |
DOIs |
|
State | Published - 2009 |
Keywords
- Cellular therapy
- Clinical translation
- Stem cell transplantation
- Tissue regeneration
ASJC Scopus subject areas
- Biomedical Engineering
- Cell Biology
- Transplantation